Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DBH | P09172 | 1/20 | 0.42 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31241086 | 0.88 | PSMB1 (0.48) | EGLN1ALDH1A1PSMB1PSMB5KMT2A | |
| SCHEMBL13392342 | 0.88 | PSMB1 (0.48) | EGLN1ALDH1A1PSMB1PSMB5KMT2A | |
| SCHEMBL6167939 | 0.85 | MAPK14 (0.52) | POLBLMNAALDH1A1SMN1; SMN2THRB | |
| SCHEMBL6169682 | 0.81 | MAPT (0.55) | MAPTTP53LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6178075 | 0.81 | PIK3R1 (0.46) | MAPTALDH1A1KDM4EPSMB1PSMB5 | |
| SCHEMBL2611357 | 0.81 | EGLN1 (0.50) | EGLN1MAPTTP53POLBLMNA | |
| SCHEMBL6168739 | 0.81 | FGFR1 (0.48) | MAPTTP53LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL31241117 | 0.80 | MAPT (0.55) | MAPTTP53POLBLMNATHRB | |
| SCHEMBL6168325 | 0.80 | MAPT (0.50) | MAPTTP53LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL28061819 | 0.79 | HDAC3 (0.47) | LMNAALDH1A1SMN1; SMN2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530472-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014379-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | MMP1, MMP13, MMP9 | EGLN1 3292/4885MAPT 2142/4885TP53 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.